Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL603520 | 1.00 | HRH3 (0.46) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| SCHEMBL603521 | 1.00 | HRH3 (0.46) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| Ammonia Solution, Strong SCHEMBL20740067 | 0.98 | HRH3 (0.45) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| SCHEMBL186721 | 0.91 | HRH3 (0.51) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| SCHEMBL28492122 | 0.91 | HRH3 (0.51) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| SCHEMBL1295721 | 0.91 | HRH3 (0.51) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| SCHEMBL26999357 | 0.88 | CHRM2 (0.44) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| SCHEMBL1139458 | 0.88 | CHRM2 (0.44) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| SCHEMBL9651542 | 0.88 | CHRM2 (0.44) | HRH3CHRM2CHRM1CHRM3MAPK1 | |
| SCHEMBL27039485 | 0.85 | HPGD (0.57) | HRH3HPGDKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106949-A1 | WRN INHIBITORS | RADD PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3818047-B1 | NOVEL COMPOUNDS FOR CONTROLLING ARTHROPODS | BAYER ANIMAL HEALTH GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| US-11357755-B2 | Compounds for controlling arthropods | BAYER ANIMAL HEALTH GMBH (DE) | 2022-06-14 | — | — | US | disclosed |
| US-9051255-B2 | Piperazinyl cyclohexane compounds as GPR38 agonists | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-09 | — | — | US | disclosed |
| EP-2234978-B1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2015-02-25 | — | — | EP | disclosed |
| US-20140221391-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140221392-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2623492-B1 | CYCLOHEXANE DERIVATIVE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-7994179-B2 | Carbamoyl compounds as DGAT1 inhibitors 190 | ASTRAZENECA AB (SE) | 2011-08-09 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009081195-A1 | CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20080234271-A1 | Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them | ICOS CORPORATION (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1740561-A2 | ARYLPHENYLAMINO-AND ARYLPHENYLETHER-SULFIDE DERIVATIVES, USEFUL FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ICOS Corporation (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105766-A2 | ARYLPHENYLAMINO-AND ARYLPHENYLETHER-SULFIDE DERIVATIVES, USEFUL FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ICOS CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739101-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, HIPK2 | HRH3 2184/4885CHRM2 4870/4885CHRM1 4869/4885 |
| US-20120108602-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | HRH3 3294/4885CHRM2 2613/4885CHRM1 1101/4885 |
| US-20140221392-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | HRH2, CBR1, HRH4 | HRH3 24/4885CHRM2 107/4885CHRM1 48/4885 |
| US-20140221391-A1 | CYCLOHEXANE DERIVATIVE COMPOUND | HRH2, CBR1, HRH4 | HRH3 24/4885CHRM2 107/4885CHRM1 48/4885 |
| US-20080234271-A1 | Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them | HPGDS, AHR, TST | HRH3 807/4885CHRM2 3090/4885CHRM1 3959/4885 |
| US-11357755-B2 | Compounds for controlling arthropods | DDT, AAAS, AGO2 | HRH3 1230/4885CHRM2 2998/4885CHRM1 2826/4885 |
| US-20090298853-A1 | Carbamoyl Compounds as DGAT1 Inhibitors 190 | DGAT1, DGAT2, SOAT1 | HRH3 3316/4885CHRM2 2629/4885CHRM1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.